#USA #New York #Securities Class Action #Faruqi Law #AQST

Urgent Legal Action for Aquestive Therapeutics Investors

As the deadline for a securities class action lawsuit approaches, investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) are urged to take immediate action. Faruqi & Faruqi, LLP, a national securities law firm, is investigating possible claims against the company and reminds affected investors of the critical deadline of May 4, 2026. This could mark a significant opportunity for those who acquired securities in the company between June 16, 2025, and January 8, 2026.

The foundation of this case lies in allegations that both the company and its executives made misleading statements regarding the state of their New Drug Application (NDA) for Anaphylm. This NDA is particularly important as it relates to a medication aimed at treating severe allergic reactions. It has been reported that the potential risks and human factors associated with the medication's administration were not adequately disclosed to investors, which raises concerns about the transparency of the company's communications.

On January 9, 2026, a significant announcement from the President and CEO of Aquestive highlighted identified deficiencies in the NDA that halted discussions about labeling and post-marketing commitments. Following this announcement, Aquestive's stock experienced a steep decline, dropping $2.30 or 37.04%, indicating the high stakes involved for investors linked to these events.

Who Can Join the Class Action?

Investors who believe they have been adversely affected by the actions of Aquestive are encouraged to contact Faruqi & Faruqi’s Senior Partner, Josh Wilson. As the lead plaintiff, one must showcase the greatest financial interest in the instance while being typical and adequate amongst peers in the class. Those interested in actively participating or seeking further information are advised that contacting the firm, even if not intending to serve as lead plaintiff, will not jeopardize their ability to share in any potential recovery from this class action.

Faruqi & Faruqi has built a reputable stance in representing investors since its founding in 1995, successfully securing hundreds of millions in recoveries. Individuals who might have additional insights regarding Aquestive’s operations, including whistleblowers, former employees, or shareholders, are also urged to come forward. The firm's commitment to confidentiality highlights the importance of protecting those who aid in uncovering the truth behind these allegations.

How to Take Action

To join forces in this compelling legal pursuit, affected investors should visit Faruqi & Faruqi’s website or contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Keeping abreast of ongoing developments can be crucial in understanding the implications of this case.

As this pivotal May deadline looms closer, affected investors must consider their next steps thoroughly. The outcome of this litigation could bring significant ramifications not only for the company but for all shareholders involved as well. It presents an essential opportunity to recover losses stemming from alleged misrepresentations and omissions made by the company.